When will the FDA approve Intellia Therapeutics' lonvo-z?

Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

$3.2K Vol.Closes Jan 1, 2028

Before 2028$457 Vol.69%

Before October 2027$802.1 Vol.54%

Before July 2027$1.9K Vol.27%

View on Kalshi

At a glance

What

The FDA is evaluating Intellia Therapeutics' rolling BLA submission for lonvo-z, a one-time in vivo CRISPR gene-editing therapy for hereditary angioedema.

Who

Intellia Therapeutics (NTLA) is the developer seeking approval, while the U.S. Food and Drug Administration (FDA) is the regulatory body reviewing the application.

Context

The drug candidate met its Phase 3 primary endpoint with an 87% reduction in attack rates and is positioned to become the world's first approved in vivo CRISPR-Cas gene-editing therapy.

linkedin.com fiercebiotech.com

Stakes

Approval would introduce a potential functional cure eliminating the need for recurrent therapies for patients, with the company targeting a first-half 2027 launch.

linkedin.com biopharmadive.com

Note: The marketed drug name is lonvoguran ziclumeran (lonvo-z), and the company's target timeline assumes standard or accelerated FDA review without major delays or requests for additional data.

Apr 1, 2025

A Phase 3 trial (HAELO) demonstrated that one infusion reduced swelling attacks by 87% compared to placebo over six months, meeting the primary endpoint.

fiercebiotech.com biopharmadive.com

Apr 27

Intellia Therapeutics initiated a rolling biologics license application (BLA) to the FDA for lonvo-z (formerly NTLA-2002) to treat hereditary angioedema.

ir.intelliatx.com

Apr 27

The company expects to complete the BLA submission in the second half of 2026 and anticipates a commercial launch in the first half of 2027 if approved.

ir.intelliatx.com marketbeat.com

Now

Oct 1

FDA decision on granting priority review and providing a target action date for lonvo-z evaluation, contingent on BLA filing acceptance.

ir.intelliatx.com

Dec 1

Expected completion of the rolling BLA submission for lonvo-z by the end of the second half of 2026.

ir.intelliatx.com stocktitan.net

AI-generated briefing. AI can make mistakes. This is not financial advice.

Bull case

The Phase 3 HAELO trial achieved its primary endpoint with an 87% reduction in swelling attacks versus placebo, a result analysts noted was close to the 90% bull case target.
fiercebiotech.com
Long-term Phase 1/2 data shows 100% of patients remained attack-free for up to three years after a single dose, supporting the drug's potential as a functional cure.
crisprmedicinenews.com
Intellia explicitly stated an anticipated commercial launch in the first half of 2027 if approved, which falls well before the January 1, 2028 market close date.
ir.intelliatx.com marketbeat.com

AI-generated briefing. AI can make mistakes. This is not financial advice.

Bear case

The company explicitly stated that BLA completion and regulatory acceptance are "anticipated" but not yet finalized, meaning FDA acceptance and priority review remain uncertain.
stocktitan.net
Approval is conditional on the FDA's final regulatory evaluation, and the timeline for approval could shift depending on whether the agency grants priority review or sets a later target action date.
ir.intelliatx.com stocktitan.net

At a glance

What

The FDA is evaluating Intellia Therapeutics' rolling BLA submission for lonvo-z, a one-time in vivo CRISPR gene-editing therapy for hereditary angioedema.

Who

Intellia Therapeutics (NTLA) is the developer seeking approval, while the U.S. Food and Drug Administration (FDA) is the regulatory body reviewing the application.

Context

The drug candidate met its Phase 3 primary endpoint with an 87% reduction in attack rates and is positioned to become the world's first approved in vivo CRISPR-Cas gene-editing therapy.

linkedin.com fiercebiotech.com

Stakes

Approval would introduce a potential functional cure eliminating the need for recurrent therapies for patients, with the company targeting a first-half 2027 launch.

linkedin.com biopharmadive.com

Note: The marketed drug name is lonvoguran ziclumeran (lonvo-z), and the company's target timeline assumes standard or accelerated FDA review without major delays or requests for additional data.

Apr 1, 2025

A Phase 3 trial (HAELO) demonstrated that one infusion reduced swelling attacks by 87% compared to placebo over six months, meeting the primary endpoint.

fiercebiotech.com biopharmadive.com

Apr 27

Intellia Therapeutics initiated a rolling biologics license application (BLA) to the FDA for lonvo-z (formerly NTLA-2002) to treat hereditary angioedema.

ir.intelliatx.com

Apr 27

The company expects to complete the BLA submission in the second half of 2026 and anticipates a commercial launch in the first half of 2027 if approved.

ir.intelliatx.com marketbeat.com

Now

Oct 1

FDA decision on granting priority review and providing a target action date for lonvo-z evaluation, contingent on BLA filing acceptance.

ir.intelliatx.com

Dec 1

Expected completion of the rolling BLA submission for lonvo-z by the end of the second half of 2026.

ir.intelliatx.com stocktitan.net

AI-generated briefing. AI can make mistakes. This is not financial advice.

Bull case

The Phase 3 HAELO trial achieved its primary endpoint with an 87% reduction in swelling attacks versus placebo, a result analysts noted was close to the 90% bull case target.
fiercebiotech.com
Long-term Phase 1/2 data shows 100% of patients remained attack-free for up to three years after a single dose, supporting the drug's potential as a functional cure.
crisprmedicinenews.com
Intellia explicitly stated an anticipated commercial launch in the first half of 2027 if approved, which falls well before the January 1, 2028 market close date.
ir.intelliatx.com marketbeat.com

AI-generated briefing. AI can make mistakes. This is not financial advice.

Bear case

The company explicitly stated that BLA completion and regulatory acceptance are "anticipated" but not yet finalized, meaning FDA acceptance and priority review remain uncertain.
stocktitan.net
Approval is conditional on the FDA's final regulatory evaluation, and the timeline for approval could shift depending on whether the agency grants priority review or sets a later target action date.
ir.intelliatx.com stocktitan.net